For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.
We offer closed automated solutions for manual steps in the cell manufacturing process. Our flexible automated modules provide performance gains in purifying mononuclear cells, washing contaminants from cell fractions, cell selection, and storage while significantly shortening processing times.
RANCHO CORDOVA, Calif., January 11, 2023 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the … Continued
RANCHO CORDOVA, Calif., December 21, 2022 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced a 1-for-45 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on December 22, 2022. Beginning tomorrow, December 22, 2022, the Company’s common … Continued
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., November 10, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2022 … Continued
Conference Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif., November 7, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the third quarter ended September 30, 2022, and provide a corporate strategic … Continued
RANCHO CORDOVA, CA — October 28, 2022 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the closing of its previously announced public offering of 11,783,572 shares of its common stock, $0.001 par value (the “Common Shares”), 2,892,858 pre-funded warrants to purchase … Continued
RANCHO CORDOVA, CA — October 25, 2022 — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the pricing of its public offering of 11,783,572 shares of its common stock, $0.001 par value (the “Common Shares”) (or pre-funded warrants to purchase Common Shares … Continued